Sumit Woods Q3 FY26: revenue declines, director change

Revenue DeclineResults View source PDF Explain this filing

SUMIT · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.6%Reaction day

₹50.00

prior close

₹49.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.0%+1.6% vs market

Residential Commercial Projects peers, median of 61sector+0.3%+2.3% vs sector

On the reaction day the stock moved 1.6 pts more than Nifty Microcap 250 and 2.3 pts more than its Residential Commercial Projects peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.1

10m

+2.2

15m

+0.9

30m

+0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.6+1.0+1.6+0.3+2.3

Next day

+11.6+0.5+11.1-0.0+11.6

+4.5-0.0+4.5-1.2+5.7

-2.0-1.5-0.5-3.1+1.1

-3.0-2.2-0.8-3.4+0.4

+0.0-1.2+1.2-2.9+2.9

-3.9-2.4-1.5-3.8-0.1

15d

-24.8-8.8-16.0-10.6-14.2

-30.2-8.3-21.9-12.8-17.4

-5.9-3.5-2.4-8.8+2.8

-3.4+6.4-9.8-2.9-0.5

UpDownMarket · Nifty Microcap 250Sector · Residential Commercial Projects peers, median of 61Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sumit Woods reported Q3 FY26 results. Standalone 9M revenue fell to Rs 25.58 cr from Rs 99.11 cr last year. Consolidated 9M revenue dropped 37 percent to Rs 69.28 cr from Rs 110.28 cr. Consolidated 9M net profit was Rs 4.68 cr versus Rs 6.29 cr earlier. Auditor SSRV and Associates gave an unmodified opinion. Mr. Subodh Nemlekar resigned as non-executive director due to health issues; his wife Mrs. Kavita Nemlekar appointed to fill the vacancy.

Likely market impact

Sharp revenue decline is a concern for shareholders. Director change due to health is neutral. Watch project pipeline and order book closely.